KYNTRA BIO, INC. (KYNB)
↓ Download CSV- Sector Manufacturing
- Fiscal year ends Dec 31
In fiscal 2025, KYNTRA BIO, INC. reported revenue of $6.44M, down 78.3% from the prior year. The company was profitable, with a net margin of 2848.6%. It held $119.59M in total assets against $115.12M in total liabilities.
Key ratios (FY2025)
-712.7%
Operating margin
2848.6%
Net margin
-78.3%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.44M | $29.62M | $46.80M | $140.73M | $235.31M | $176.32M | $256.58M | $212.96M | $131.00M | $183.19M |
| Cost of Revenue | $556.0K | $15.56M | $3.96M | $20.28M | $12.87M | $8.87M | $1.15M | — | — | — |
| Operating Income | -$45.90M | -$150.42M | -$322.72M | -$301.02M | -$288.53M | -$191.88M | -$89.31M | -$86.69M | -$117.28M | -$50.04M |
| Net Income | $183.45M | -$47.58M | -$284.23M | -$293.65M | -$290.02M | -$189.29M | -$76.97M | -$86.42M | -$120.88M | -$58.07M |
| EPS (Diluted) | $45.37 | $-11.89 | $-2.92 | $-3.14 | $-3.14 | $-2.11 | — | — | — | — |
| Total Assets | $119.59M | $214.53M | $423.53M | $610.09M | $773.82M | $826.84M | $857.40M | $880.60M | $898.65M | $469.55M |
| Total Liabilities | $115.12M | $398.16M | $585.73M | $611.57M | $544.71M | $385.39M | $321.99M | $352.13M | $350.91M | $294.44M |
| Shareholders' Equity | -$17.00M | -$205.12M | -$183.68M | -$1.48M | $229.11M | $441.45M | $535.41M | $528.47M | $547.74M | $135.07M |
| Cash & Equivalents | $47.87M | $50.48M | $81.55M | $155.70M | $171.22M | $678.39M | $126.27M | $89.26M | $673.66M | $173.78M |
| Operating Cash Flow | -$4.77M | -$138.00M | -$315.02M | -$145.93M | -$82.23M | $81.60M | -$78.70M | -$76.14M | -$66.51M | $7.11M |
| Capital Expenditures | $38.0K | $266.0K | $2.52M | $3.74M | $5.19M | $3.99M | $5.76M | $8.02M | $8.50M | $1.25M |
| Shares Outstanding | 4.05M | 4.04M | 98.77M | 94.17M | 92.88M | 91.44M | 87.66M | 85.43M | 82.50M | 63.66M |